Schering-Plough Corporation has announced that its wholly owned subsidiary Warrick Pharmaceuticals has launched a generic ribavirin product in the United States.
Schering-Plough had previously entered into a licensing agreement with Three Rivers Pharmaceuticals, LLC regarding Schering-Plough's U.S. ribavirin patents. Under terms of the agreement and as a result of launching Warrick ribavirin, Schering-Plough will not receive a royalty from Three Rivers on sales of Three Rivers' generic ribavirin product. Financial terms of the licensing agreement have not been disclosed.
Schering-Plough noted that the market for generic pharmaceutical products is volatile, particularly at launch, and it will price its generic ribavirin product according to market conditions and applicable regulations.
Schering-Plough markets ribavirin, USP capsules under the brand name REBETOL(R). As previously reported, Schering-Plough expected generic competition for REBETOL in the U.S. market in 2004.